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Genetically modified (GM) crops first appeared commercially in the
mid-1990s to what seemed a bright and promising future. Resistant
to pests and the herbicides used to control weeds, these new crops
were so popular with farmers that millions of acres were planted with
them by the turn of the millennium. Today, GM crops are grown
commercially by 8.25 million farmers on 200 million acres spread
throughout 17 countries, reports the International Service for the
Acquisition of Agri-Biotech Applications (ISAAA), an international
nonprofit that advocates for the technology. The world’s top five
producers—the United States, Argentina, Canada, Brazil, and
China—account for 96% of global GM cultivation; of this, more
than half is in the United States. 
Yet these impressive numbers tell only part of the story. Fully as
notable as the growth of GM agriculture is the relentless backlash
that has developed against it. Although GM supporters insist the
technology raises harvest yields, reduces agrochemical use, and will
eventually even produce high-nutrition food that can grow in deplet-
ed soils, skeptics counter that the risks of GM foods—made with
gene splicing methods from biotechnology—are unknown and
poorly addressed by current testing methods. They also worry that
the spread of GM crops, which are supplied mainly by a handful of
multinational companies, fuels corporate ownership of the seed sup-
ply and threatens the purity of indigenous crops, with which GM
varieties can breed by cross-pollination. 
A Growing Backlash
The opposition’s attacks are generating sustained impacts. In April
2004, biotech companies including Novartis Seeds, Aventis
CropScience, and Bayer CropScience abandoned GM field trials in
England, citing challenges raised by British consumers. The next
month, Monsanto dropped its new variety of herbicide-resistant wheat
despite hundreds of millions reputedly spent on research and develop-
ment. The product was shelved in part because of threatened boycotts
by Europe and Japan, which together buy 45% of all U.S. wheat
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exports, according to the U.S. Department of
Agriculture Economic Research Service
(UDSA/ERS). And in November 2004, the
world’s largest agrochemical company, the
Swiss-based Syngenta, moved its European
GM field trials to the United States, also cit-
ing public resistance. 
Europe itself, where commercial GM
crops are grown only in Spain—and there in
small amounts—is politically gridlocked
over the issue, says Geoffrey Lean, environ-
ment editor for The Independent on Sunday,
a British newspaper. The European Com-
mission lifted a six-year moratorium on GM
food in Europe last year, but even so, no new
crops have been granted entry, he says. The
commission, which favors the technology,
wants to allow more GM imports. However,
a number of opposing countries—notably
Austria, France, Portugal, Greece, Denmark,
and Luxembourg—have so far prevented
this from happening. “As far as opinions in
Europe go, the public is heavily against
GM, the scientific community is for it, and
governments are split down the middle,”
Lean says.
Developing countries are also heavily
divided, even though they could arguably
benefit the most from the technology. Some
stakeholders worry that the introduction of
GM seed in developing countries could
threaten the purity of conventional crops,
thus posing a risk to food exports bound for
markets that reject the technology. 
Meanwhile, a slew of “GM-free zones,”
where all transgenic organisms are banned
(including fish, other animals, and plants
used to make drugs), are cropping up
around the world. Three are in the
United States, all in California. More
than 3,000 are found throughout
Europe, with others in Canada,
Australia, and the Philippines, says
Renata Brillinger, director of the citi-
zens group Californians for GE [genet-
ically engineered]-Free Agriculture. 
GM crops also suffer a poor repu-
tation among the general public, in
part because they are made in ways that
can sound scary when described to
consumers. Biotechnology allows sci-
entists to combine genes from totally
unrelated species of plants, microbes,
and animals. How is this possible?
There are several methods. In one, bac-
teria and viruses—which are naturally
able to penetrate cells—are deployed as
delivery vehicles to shuttle genes direct-
ly into plant cell genomes. In another,
tiny particles coated with a gene are
propelled at high speeds into cells to
deliver the gene. In still another, elec-
tric shocks are used to destabilize cell
membranes, making them permeable
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Source: Center for Food Safety. April 2005. Available at: http://www.centerforfoodsafety.org/geneticall5.cfm.to delivered genes. These and several other
methods enable scientists to evade natural
barriers that cells use to protect themselves
from foreign DNA.
Thus, genes from bacteria can be intro-
duced into a plant—or, as in one instance, a
fish gene can be introduced into a tomato.
Monsanto has made pest-resistant varieties
with a gene from Bacillus thuringiensis (Bt), a
bacterium that kills certain types of insects.
The resultant varieties produce the Bt toxin,
a protein that is lethal to these insects but safe
for humans. DNA Plant Technology of Oak-
land, California (which has since gone out of
business) was the company responsible for
inserting a fish gene into a tomato. In that
case, an “anti-freeze” gene that helps flounder
survive frigid waters was spliced into tomato
cells to enhance the plant’s resistance to cold.
The fish-tomato didn’t swim, nor did it ever
make it to market. But its memory lingers as
a quintessential “frankenfood” that GM crit-
ics often refer to. 
Dwindling Varieties
With growing opposition to GM crops has
come a remarkable drop in new varieties
being introduced by the agrobiotech indus-
try. A 2 February 2005 report by the Center
for Science in the Public Interest (CSPI), an
environmental group, observes that three-
quarters of federal approvals for GM crops in
the United States were obtained between
1995 and 1999. 
According to Gregory Jaffe, director of
the Project on Biotechnology at CSPI, most
of the new crops that drive GM agriculture’s
growth now are cookie-cutter varieties that
merely recycle the same genes for pest and
herbicide resistance already used in existing
products. Indeed, virtually all the GM crops
grown today are different varieties of the
same four crops that became available
before 2000, mainly pest- or herbicide-
resistant varieties of corn, cotton, soybeans,
and canola. 
These crops were made for and marketed
specifically to farmers, who make up the
industry’s key buyers. Farmers have embraced
GM technology because it saves them time
and money. Monsanto’s Roundup Ready
crops, for instance, are resistant to the
glyphosate-based herbicide Roundup. Farm-
ers can eliminate weeds with one or two
sprayings of the wide-spectrum herbicide
without harming their crops. 
Rob Rose, a spokesman for the Donald
Danforth Plant Science Center, a nonprof-
it research facility funded partially by the
agrobiotech industry, says companies barely
considered the consumers who would buy
and eat GM foods in their initial marketing
efforts. This proved to be a mistake, he says.
When the consumer backlash started,
companies were caught off-guard. “Even
now, as the backlash intensifies, they haven’t
come up with an effective consumer market-
ing strategy,” Rose says.
To improve its public image, the agro-
biotech industry has more recently begun
promoting the concept of extra-nutritious,
environmentally resilient crops to fight world
hunger. But so far, none of these so-called
second-generation crops have entered the
marketplace, anywhere in the world.  
The second-generation crops that are in
the pipeline seem to be stuck there, mainly
because of market uncertainties, insiders say.
For example, Monsanto is developing grains
to make cooking oils with lower saturated fats
and higher levels of omega-3 fatty acids,
which are thought to protect against heart
disease. But Christopher Horner, director of
public affairs for Monsanto, acknowledges
that these grains have distant and unknown
release dates. 
Universities and small research centers
also develop second-generation GM crops,
but they lack the resources necessary to put
them on the market. The Danforth Center,
for instance, has developed numerous such
crops, including grains enriched with vita-
min E and vegetables with enhanced folate
levels, a nutrient that protects against neural
tube defects in newborns as well as cancer
and cardiovascular disease in adults. Center
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Crops and cops. In Lincolnshire, England, a protester from the group Genetix Snowball digs
up a GM sugar beet in protest as policemen intervene.Environmental Health Perspectives • VOLUME 113 | NUMBER 8 | August 2005 A 531
scientists have also developed a nutritionally
enhanced variety of cassava, a root vegetable
that is a dietary staple for hundreds of mil-
lions worldwide. 
At the University of California, Berkeley,
Peggy Lemaux, a faculty member in the
Department of Plant and Microbial Biology,
and her colleague Bob Buchanan recently
helped create a type of GM wheat that peo-
ple with wheat allergies might eat more safe-
ly. She and her colleagues at Berkeley are now
working on enhancing sorghum, another sta-
ple of the world’s poor, to make it more nutri-
tionally complete and calorie-rich. 
“I want to help people,” Lemaux says. “I
work for a land-grant university, and our
charge is to develop varieties that help agri-
culture and consumers. If I can do this for
countries that really need it, then that’s what
I want to do.” 
But Lemaux and Karel Schubert, a
Danforth Center principle investigator, both
acknowledge that despite the potential bene-
fits, the commercial value of these crops is
limited. Without significant financial back-
ing, universities and research centers can’t
fund the extensive regulatory and patent
reviews needed to bring the products to mar-
ket. But as consumers increasingly turn
against GM food, Lemaux adds, industry and
federal funds for second-generation crop
research and development are drying up. 
“Second generation crops are developed
in universities, and then those projects die,”
Lemaux says. “There’s a pall hanging over
GM and its products, so many companies
have stopped supporting fundamental
research.” Her grant from the U.S. Agency
for International Development has been cut
from a three-year to a one-year commitment.
The Question of Health Risks
Despite public fears, the health risks of eat-
ing commercialized GM foods on the mar-
ket now appear to be negligible, experts say.
Nearly 45% of the corn and 85% of the soy-
beans grown in the United States are
transgenic, according to the USDA/ERS.
Consumers are eating these foods without
any apparent health effects, although some
stakeholders caution that greater postmarket
surveillance is needed to confirm this.
As part of research and development,
GM foods are tested for safety, specifically
to ensure they don’t contain compounds
that might cause allergic reactions among
those who eat them. How might this hap-
pen? Consider how biotechnology works:
Scientists take genes from one species and
incorporate them into the genome of anoth-
er. The modified genes in the transgenic
hybrid are designed to make proteins that
ideally will do something useful, like deter
pests or boost nutrition. But these same
proteins might also be allergenic; in fact, most
known allergens are protein molecules.
The only way to confirm that a trans-
genic protein is or is not an allergen is to test
it in large numbers of people. But of course,
large-scale human testing isn’t practical or
ethically possible. Therefore, scientists resort
to surrogate tests to predict whether the
transgenic protein will elicit a human allergic
response. 
These tests have evolved considerably
since GM crops were first introduced. In the
early 1990s, scientists would test transgenic
proteins with serum obtained from people
known to be allergic to the gene sources of
the modified plant. If a protein reacted with
a serum antibody called IgE—which plays a
role in nearly all allergies—it was flagged as
an allergen. In 1993, scientists using this
approach detected allergenicity in a trans-
genic soybean containing a gene from Brazil
nuts. This soybean—created by Pioneer, now
a subsidiary of Dupont—was to be used as a
nutrition-enhanced poultry feed (Brazil nuts
are high in methionine, an essential amino
acid that soybeans lack). If commercialized, it
could have posed serious health risks to farm-
ers working with the feed: Brazil nuts can be
fatal if you’re allergic to them. But the trans-
genic protein tested positive in the serum
assay, so the soybean was pulled during early
development and destroyed.
Steve Taylor, codirector of the Food
Allergy Research and Resource Program at
the University of Nebraska, discovered the
soybean/Brazil nut problem while under con-
tract to Pioneer. He says scientists took close
note of the incident. Today, he adds, compa-
nies reduce the risk of similar problems by
avoiding genes from known allergens, 90%
of which are attributed to just eight foods
(eggs, cow’s milk, peanuts, tree nuts, fish,
shellfish, soybeans, and wheat). 
The serum test would still be optimal for
screening genes from known allergenic
sources, Taylor says. But because no one uses
genes from these sources anymore, the test is
rarely used. Instead, companies now rely
largely on initial screens that compare trans-
genic proteins to the structures and charac-
teristics of known allergens. 
In one such method, known as sequence
homology, scientists compare a transgenic
protein’s amino acid sequence with the
sequences of known allergens in a database. If
the protein shares a predetermined level of
similarity with one or more allergens, then it
is flagged for further study. Several databases
have emerged to meet this need; one of these,
developed by the Food Allergy Research and
Resource Program, contains nearly 1,200
allergens and is growing steadily. 
Another method exploits the fact that
most allergens are large and resistant to stom-
ach acids. Called the pepsin digestibility
assay, this test exposes proteins to simulated
stomach fluids for varying durations. Most
allergens survive for up to an hour, whereas
nonallergens degrade within 15–30 seconds.
If these initial screens suggest that a trans-
genic protein is allergenic, companies can use
serum testing for further confirmation. If
allergenicity is still indicated, then efforts to
further develop the GM variety are typically
abandoned. 
Agronomists have long known that con-
ventional plant breeding can produce aller-
genic compounds. For instance, the Chinese
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The labeling dilemma. Some stakeholders claim that labeling of GM foods would go a long
way toward assuring consumers that they have a choice in whether to consume such products,
although studies have shown consumers are likely to avoid GM items labeled as such.gooseberry, a small, somewhat bitter fruit,
was conventionally modified in New Zea-
land to make kiwifruits, which produced
allergic reactions among some consumers,
although the modified fruits remain popular
at produce markets. A key question is
whether transgenic proteins have more aller-
genic potential than those produced by con-
ventional plant breeding.
After more than a decade of testing and
debate, the emerging consensus among scien-
tists is that they do not. The National
Academy of Sciences recently expressed this
view in its 2004 report Safety of Genetically
Engineered Foods: Approaches to Assessing
Unintended Health Effects, which stated,
“The process of genetic engineering has not
been shown to be inherently dangerous but
rather, evidence to date shows that any tech-
nique, including genetic engineering, carries
the potential to result in unintended changes
in the composition of the food.”
The U.S. Regulatory System
As far as U.S. regulatory agencies are con-
cerned, agrobiotech companies need only
demonstrate that—apart from the transgenic
protein—a GM crop shares equivalent com-
position and nutritional status to its conven-
tional counterpart. If this is shown to be the
case, then the crop is said to be as safe as the
conventional variety, and companies are free
to sell it. Crops that contain a pesticidal pro-
tein such as Bt toxin must undergo manda-
tory allergenicity testing coordinated by the
Environmental Protection Agency. All other
GM traits are evaluated by voluntary consul-
tations with the Food and Drug Admin-
istration (FDA). During these consultations,
FDA and company representatives discuss
procedures, and the companies disclose data
and describe testing methods and results. The
FDA recently introduced draft guidance on
testing that encourages companies to come in
at the very early stages of the process, when
they are still in planning stages.
GM opponents have long argued that
FDA consultations should be mandatory.
But Jason Dietz, a consumer safety officer at
the FDA’s Center for Food Safety and
Applied Nutrition, says that in the adminis-
tration’s view, the risks posed by transgenic
crop breeding aren’t great enough to warrant
mandatory testing. Moreover, he adds, com-
panies are liable for the health risks of GM
foods under the safety provisions of the
Federal Food, Drug, and Cosmetic Act. 
The best way for companies to ensure
their compliance with the act, Dietz says, is
to undergo a premarket consultation with the
FDA. “To our knowledge, all [GM] foods
intended to be commercialized in the United
States have been through the consultation
procedure,” he says.
An important and unresolved question is
whether current testing methods will be ade-
quate for second-generation crops. All the
pest- and herbicide-resistance traits used now
are found at minute levels in the plants, far
below those likely to produce allergic
responses, according to Taylor. But in some
second-generation varieties, GM traits are
intentionally expressed at high levels that
change the nature of the food. 
Taylor suggests that uncertainties about
second-generation crop testing exacerbate the
agrobiotech industry’s reluctance to develop
these markets further. “Because [the plant’s]
composition is significantly altered, and com-
ponents are expressed at high levels, second-
generation crops will probably require more
extensive safety evaluation,” he says. “One of
the key issues is that there is no international
agreement on what will be required. The
uncertainty is considerable, and that creates
hesitancy on the part of companies. Regu-
latory approvals will be less certain, consumer
acceptance is a hurdle, and scientific uncer-
tainty about how to proceed with safety
assessment causes worry.” 
The Labeling Scene
In many countries, debates over GM foods
have been accompanied by growing demands
for an international labeling scheme to segre-
gate transgenic and conventionally grown
products. Labeling isn’t required in the
United States because regulatory agencies
here don’t view commercialized GM food as
materially different from conventional vari-
eties. However, the European Union does
require it, and countries including Australia,
Japan, and New Zealand, among others, have
either established labeling systems or are in
the process of doing so.
GM labeling is a tricky proposition that
U.S. companies would rather avoid. Some
surveys have shown that consumers are less
likely to buy foods that they know are GM.
Not only does labeling threaten markets, it
could also be hard to implement, says Alan
McHughen, a biotech specialist and geneti-
cist at the University of California, Riverside.
With few exceptions, most commodity
crops grown in the United States aren’t seg-
regated once they reach the supply chain.
Thus, both GM and conventionally grown
nonorganic crops can wind up in the same
containers as they make their way through
distribution channels.
McHughen says the challenge is to
somehow guarantee that GM labeling is
accurate and credible, which is no easy task.
“From the farmer, to the county elevator, to
the rail or barge that carries bulked grain to
terminals, to the retailers—every step [in the
labeling process] would have to be moni-
tored and verified,” he says.
Even so, labeling is necessary because
food distribution is increasingly globalized,
says Juan Lopez, international coordinator
for biosafety with Friends of the Earth, a
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nongovernmental organization. The prob-
lem, he emphasizes, is that without a com-
prehensive labeling system, GM products can
wind up in countries that don’t want them. 
Some recent high-profile episodes have
heightened these concerns. In late 2004,
Syngenta announced it had accidentally put
a controversial type of GM corn on the mar-
ket in the United States and Europe during
the previous four years. The corn, known as
Bt10, differs from a similar variety called
Bt11 by only a few nucleotides. But whereas
Bt11 has been approved in Europe, Bt10
never underwent review and thus is consid-
ered illegal in Europe. The accident pro-
duced no known illnesses, but many seized
on it as further justification for labeling.
Syngenta’s woes with Bt10 have only contin-
ued: in early summer 2005, large commodi-
ty corn shipments in Japan were found to be
comingled with Bt10, and a similar comin-
gled shipment was intercepted in Ireland. 
While Syngenta was grappling with its
botched shipments, the 119 signatories of
the United Nations Cartagena Protocol on
Biosafety (a supplementary agreement of the
Convention on Biological Diversity) were
deciding whether to create documentation
requirements for bulk shipping of “living
modified organisms,” which are the live GM
organisms such as seeds (rather than milled
forms such as flour). But this initiative failed
during last-minute negotiations at a meeting
in Montréal on 3 June 2005. Protocol rules
require consensus for passage, which couldn’t
be reached because Brazil and New Zealand
refused to sign on, claiming the paperwork
would be excessive and costly. (The United
States is not a party to the Convention on
Biological Diversity and therefore cannot be
a party to the Cartagena protocol.) The fail-
ure means the burden of proof for ensuring
GM-free shipments remains with importers,
Lopez says. 
“This would have been the first time a
global system for the identification of [GM
organisms] would have been in place,” he
adds. “But countries at the national and
regional level are working to implement
identification and labeling schemes anyway.” 
The Future
Today, GM agriculture’s future seems hard
to predict. Its growth is undeniable—
ISAAA figures indicate that global acreage
of GM crops increased by 20% in 2004
with no sign of slowing. But the vast major-
ity of this growth occurred in just a handful
of countries planting just a handful of crop
varieties. The new second-generation crops
that comprise the bulk of the industry’s
consumer marketing efforts appear to be
largely stalled, held at bay by market uncer-
tainty and the voracious attacks of environ-
mental groups. 
Consider the plight of Golden Rice, the
product of a largely humanitarian effort led
by Syngenta and a consortium of nonprofit
research groups. Golden Rice was meant as a
means to boost daily intakes of vitamin A;
deficiency-related blindness and death cur-
rently afflicts nearly 2 million people annual-
ly, according to the United Nations
Children’s Fund. However, Golden Rice is
under sustained assault by Greenpeace,
which claims that health effects have not
been sufficiently addressed, that the rice
could breed with and contaminate wild vari-
eties, and that the whole effort is merely a
ploy to gain acceptance for GM food in
developing countries. Jorge Mayer, manager
of the Golden Rice Project at the University
of Freiburg in Germany, as quoted in the 2
April 2005 New Scientist, countered that
Greenpeace’s blanket opposition to Golden
Rice is impeding the very trials that will pro-
vide the answers the group demands. “It’s a
catch-22,” he said. 
So what is the truth of the matter? A
conclusive answer isn’t easy to find. Biotech
companies claim GM technology will help
feed the world’s poor, but how do they
intend to protect intellectual property in
developing markets? Despite repeated ques-
tioning, sources for this article could not
provide a clear answer to that question.
Companies have sued farmers for saving
seeds from their GM varieties and planting
them without payment for intellectual prop-
erty; Monsanto has more than 100 such law-
suits ongoing in the United States today, says
Horner. Will farmers in developing coun-
tries also have to pay for GM seeds, year after
year? What will that mean for traditional
agriculture, which depends on the age-old
practice of saving seeds for future planting?
While these questions remain, studies
show that GM technology can produce
important benefits. Carl Pray, a professor of
agriculture, food, and resource economics at
Rutgers University, recently concluded a
study showing that growing Bt rice in China
reduced by half the number of chemical pes-
ticide poisonings among farmers. His research
also showed that farmers who planted the rice
saved money with increased crop yields and
reduced chemical pesticide use. His results are
published in the 29 April 2005 issue of
Science. “I’m convinced [the crops] are a pos-
itive development for China,” Pray says. 
Other farmers who grow GM crops echo
these sentiments. Given that GM agriculture
is here to stay, the optimal scenario for the
future—and the likely eventual outcome—is
a dual supply chain, one that clearly distin-
guishes GM from non-GM products. In the
meantime, the rhetoric and spin that sur-
rounds this most heated of environmental
battles will go on. 
Charles W. Schmidt
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Boon or bane? At the GMO Research Centre in Los Banos, Philippines, a scientist
examines GM rice plants. New varieties of GM plants offer the promise of better
yields and improved nutritional value; opponents contend that such benefits may
come at too high a price. For example, Golden Rice (pictured above in two varieties,
along with white conventional rice) could boost daily intakes of vitamin A and fight
deficiency-related blindness and death. However, the activist organization Green-
peace protests that the rice hasn’t been adequately tested for potential adverse
health and environmental effects.